Stemline Therapeutics, Inc. (NasdaqCM:STML) will look for acquisitions. Stemline Therapeutics has Closed a $92 Million Public Offering of Common Stock. Stemline intends to use the net proceeds from the offering for commercial activities of ELZONRIS (tagraxofusp; SL â401) including clinical trials for additional indications including chronic myelomonocytic leukemia (CMML), myelofibrosis (MF) and other diseases, clinical development of SL â801, SL â701 and potentially SL-901, research and development activities, potential acquisitions and in-licensing and other general corporate purposes.